HTRS2025.O8C.4 Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Results From the Phase 3 AFFINE Gene Therapy Trial

Lignende værker

• HTRS2025.P1.25 Efficacy and Safety of Fidanacogene Elaparvovec Gene Therapy in US Adults With Hemophilia B: A Subgroup Analysis of the BENEGENE-2 Gene Therapy Trial
  af: Adam Cuker, et al.
  Udgivet: (2025-11-01)
• HTRS2025.O8C.4 Efficacy and Safety of Giroctocogene Fitelparvovec in Adults With Moderately Severe to Severe Hemophilia A: Results From the Phase 3 AFFINE Gene Therapy Trial
  af: Caroline Berube, et al.
  Udgivet: (2025-11-01)
• Prospective Evaluation of Non-Compliant Severe Hemophilia Patients
  af: Mehmet Can Uğur, et al.
  Udgivet: (2019-05-01)
• New Treatment Modalities in Hemophilia
  af: Kaan Kavaklı
  Udgivet: (2022-03-01)
• A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab
  af: Davide Matino, et al.
  Udgivet: (2026-06-01)